Urvi A. Shah, MD
Multiple Myeloma; Smoldering Myeloma; Monoclonal Gammopathy of Undetermined Significance (MGUS); Related Plasma Cell Disorders
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Shah accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Grant Medical College
Internal Medicine - Tufts Medical Center
Adult Cancer Immunotherapy - Memorial Sloan Kettering Cancer Center; Hematology and Medical Oncology - Montefiore Medical Center & Albert Einstein College of Medicine
Internal Medicine; Medical Oncology; Hematology
I am a board-certified hematologic oncologist with expertise in diagnosing and treating plasma cell disorders. These include multiple myeloma, smoldering myeloma, and monoclonal gammopathy of undetermined significance, among others. I work as part of a multidisciplinary team caring for people with these cancers.
During my oncology fellowship training, I needed chemotherapy for Hodgkin’s lymphoma. My firsthand experience on the other side of the doctor-patient relationship has helped me relate to patients in a more compassionate and empathic way. I find that clear, effective communication with patients, family members, and doctors can be crucial to prevent unnecessary stress and help in recovery.
I conduct clinical and translational research into plasma cell disorders. My research focuses on developing and testing new treatments for these disorders. I am particularly interested in the role of nutrition, the microbiome, epigenetics, and the immune system in the development of these diseases. Thus, identifying methods to prevent its progression or relapse.
I am currently involved in a number of clinical trials that are looking at novel immune therapies, including chimeric antigen receptor T cells. At MSK, our patients have access to the latest therapies, including immune-based therapies for plasma cell disorders. Sometimes this is through a clinical trial but it can also be part of our standard care. I value patients’ goals for their care and treatment very strongly. I work closely with them to come up with a care plan that suits their needs and also allows the best possible treatment strategy.
In my free time, I enjoy painting with mixed media, staying active, and being outdoors, especially hiking trails around New York City.
I find that clear, effective communication with patients, family members, and doctors can be crucial to prevent unnecessary stress and help in recovery.
Awards and Honors
- Henry L. Moses Prize for Best Clinical Paper, Montefiore Medical Center (2019)
- ASCO/AACR Methods in Clinical Cancer Research Workshop (2018)
- Second Place, Outstanding Fellow Research Award, Albert Einstein College of Medicine and Montefiore Medical Center Research Symposium (2018)
- American Society of Hematology Abstract Achievement Award (2017)
- ECOG-ACRIN Young Investigator Symposium Distinction Award for Translational Research (2017)
- Chief Fellow, Hematology Rotation, Montefiore Medical Center (2017)
- Outstanding Emergency Department Resident Award, Tufts Medical Center (2015)
- Clinical Trials Investigated by Dr. Shah
- A Phase III Study Comparing JNJ-68284528 CAR T-Cell Therapy with a Combination of Standard Medical Treatments in Patients with Recurrent or Persistent Multiple Myeloma
- A Pilot Study of Lenalidomide and CC-486 with Radiation Therapy in Patients with Plasmacytoma
- A Study Comparing Daratumumab and Lenalidomide as Maintenance Therapy for Multiple Myeloma
- Clinical Trials Co-Investigated by Dr. Shah
- A Phase I Study of ALLO-647 with ALLO-715 CAR T-Cell Therapy in People with Recurrent or Persistent Multiple Myeloma
- A Phase I Study of BFCR4350A in People with Previously Treated Multiple Myeloma
- A Phase I Study of CC-98633 CAR T-Cell Therapy in People with Recurrent or Persistent Multiple Myeloma
- A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma
- A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Blood Cancers
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone versus Standard of Care to Achieve MRD Negativity in Patients with Newly Diagnosed Multiple Myeloma (ADVANCE study)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Shah UA, Chung E, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat T, Mai Y, Wei Y, Ishida E, Choudhary G, Joseph A, Rice R, Gitego N, Bartenstein M, Goel S, Mantzaris I, Shastri A, Parrish C, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma V, Ye BH, Janakiram M. North American ATLL has a Distinct Mutational and Transcriptional Profile and responds to epigenetic therapies. Blood 2018 Aug 13, PMID: 30104217.
Visit PubMed for a full listing of Dr. Shah’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Urvi A. Shah discloses the following relationships and financial interests:
Physicians' Education Resource
Provision of Services
Plant Powered Metro New York
Provision of Services (uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.